Could a blood pressure pill protect your liver from cancer?
NCT ID NCT04550481
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether lisinopril, a widely used blood pressure medication, can prevent liver damage from getting worse in people with non-alcoholic fatty liver disease (NAFLD). The study enrolls 45 adults with advanced liver scarring and measures changes in fibrosis markers over time. If successful, lisinopril could offer a simple, repurposed treatment to reduce liver cancer risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lisinopril
What this could lead to
If it works, this could point toward a new use for a common blood pressure drug to slow liver damage and lower liver cancer risk in people with fatty liver disease.
What could go wrong
This is a small, early-phase trial with only 45 participants, so results may not apply widely. Lisinopril may not reduce fibrosis or cancer risk as hoped, and it can cause side effects like dizziness or kidney issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONALCOHOLIC STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States